The new drug, NaQuinate, has completed its first human trials

announced yesterday that it had completed NaQuinate's first human trial. NaQuinate is a type of pyrethroic acid that is currently under development as a new oral drug for osteoporosis.
The first human trial in healthy adults, launched last year, studied single- and multi-dose NaQuinate. The main purpose is to evaluate safety, tolerance and pharmacodynamics.“ We are pleased that the last drug was completed in the first human trial. There were no significant safety or tolerance issues in the tests up to the highest dose, which supported our expectations of NaQuinate safety and good tolerance," said Dr. Cnk Oguz, Chief Medical Officer, Haoma Medica.“ Our preclinical studies reveal an exciting feature of NaQuinate, a drug that appears to coordinate with the body's natural response to weight-taking motion and work together to enhance bone formation at the time and place required. This suggests that it is an 'intelligent' drug. Dr Steve Deacon, chief executive of Haoma Medica, said. This combination of safety data from the first human study supports NaQuinate therapy to provide a safe, novel and intelligent treatment for bone diseases such as osteoporosis and to better safeguard the potential for healthy bone aging. Previous

NaQuinatehas shown that NaQuinate prevents a reduction in bone mass and quantity due to ovarian removal in rodent models. In a mechanical mouse load model that replaces weight-carrying motion, NaQuinate is able to enhance the body's normal response to load in a collaborative manner by forming bone and targeting the associated cortonic bone region. The synergy between NaQuinate and mechanical load indicates the functional use of skeletal mechanics regulation mechanisms in bone mass and bone structure regulation. Bone mechanics regulation mechanism is a term used to describe the effect of mechanical load on bone structure. NaQuinate is currently evaluating bisphosphonates with treatment models for osteoporosis, as well as load models with assulated hormones;Osteoporosis relatedOsteoporosis is a hidden disease that usually shows no signs or symptoms until a fracture occurs. It has therefore been a disease that has not been adequately diagnosed and treated.Osteoporosis leads to bone loss and changes in bone mass and strength, which occur during normal aging processes that lead to fragile bones. Fragile bones can lead to fractures, which in turn lead to disability, loss of independence and increased mortality, as well as a significant social and economic burden. Fragile fractures are a major obstacle to health in old age. Worldwide, brittle fractures occur every 3 seconds.According to the International Osteoporosis Foundation, about 200 million people worldwide suffer from the disease. The combined risk of fractures over the life cycle is 40%, comparable to the risk of cardiovascular disease. Osteoporosis takes longer to stay in hospital than many other diseases, including breast cancer, heart disease and diabetes, in women over the age of 45.About Haoma
Haoma Medica is a clinical biotech company focused on developing treatments that maintain bone and vascular health. (aoma Medica Corporate Website)